RITONAVIR (ritonavir) by Cipla is hiv protease inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2018.
Drug data last refreshed 20h ago
HIV Protease Inhibitors
Cytochrome P450 3A Inhibitor
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
Worked on RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.